A lawsuit was filed on behalf of investors in BioScrip Inc (NASDAQ:BIOS) shares over alleged securities laws violations. Deadline: November 29, 2013. NASDAQ:BIOS investors should contact the Shareholders Foundation at email@example.com
San Diego, CA -- (SBWIRE) -- 10/14/2013 -- An investor, who purchased shares of BioScrip Inc (NASDAQ:BIOS), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by BioScrip Inc in connection with certain allegedly false and misleading statements made between August 8, 2011 and September 20, 2013
Investors purchased shares of BioScrip Inc (NASDAQ:BIOS) have certain options and for certain investors are short and strict deadlines running. Deadline: November 29, 2013. NASDAQ:BIOS investors should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint the plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired securities of BioScrip Inc (NASDAQ:BIOS) between August 8, 2011 and September 20, 2013, that BioScrip Inc and certain of its officers and directors violated federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
More specifically, the plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that BioScrip Inc improperly distributed the product Exjade through its specialty pharmacy operations, that BioScrip Inc was in violation of certain federal and state laws and regulations, and that as a result of the foregoing BioScrip's statements were materially false and misleading at all relevant times.
On September 23, 2013, BioScrip Inc disclosed that the Company received a civil investigative demand issued by the United States Attorney's Office for the Southern District of New York and a subpoena from the New York State Attorney General's Medicaid Fraud Control Unit, regarding the distribution of the Novartis Pharmaceuticals Corporation product Exjade(R) by the Company's legacy specialty pharmacy division.
Shares of BioScrip Inc declined from $11.72 per share on Sept. 20, 2013, to $8.31 per share on Sept. 25 2013.
On Sept. 30, 2013, NASDAQ:BIOS shares closed at $8.78 per share.
Those who purchased shares of BioScrip Inc (NASDAQ:BIOS), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego